Nuvation Bio Files 8-K on Financials

Ticker: NUVB · Form: 8-K · Filed: May 7, 2025 · CIK: 1811063

Sentiment: neutral

Topics: financial-reporting, corporate-actions

Related Tickers: NUVB

TL;DR

Nuvation Bio dropped an 8-K on May 7th detailing financials. Check it out.

AI Summary

Nuvation Bio Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Panacea Acquisition Corp. and changed its name on April 30, 2020.

Why It Matters

This 8-K filing provides an update on Nuvation Bio's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any new material risks.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was Nuvation Bio Inc. previously known by another name?

Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp., with the name change occurring on April 30, 2020.

What is the principal executive office address for Nuvation Bio Inc. as listed in the filing?

The address listed for the principal executive office is 1500 Broadway, Suite 1401, New York, NY 10036.

What is the Standard Industrial Classification (SIC) code for Nuvation Bio Inc.?

The SIC code for Nuvation Bio Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the fiscal year end for Nuvation Bio Inc.?

The fiscal year end for Nuvation Bio Inc. is December 31 (1231).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 7, 2025 regarding Nuvation Bio Inc. (NUVB).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing